Fluonic to Present at Biotech and HealthCare Investor Conference

Share Article

White Hat Investors 2014 showcases digital health and information company.

News Image

The Arizona Bioindustry Association has selected Fluonic, Inc., to present at the White Hat Investors 2014 conference Sept. 17-18 in Phoenix.

Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s products solve the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows.

White Hat Investors 2014, taking place at the Hyatt Regency Phoenix, is the first annual biotech and healthcare investor conference that showcases select biotech and healthcare pioneers in the Rocky Mountain & Southwest regions. Bioindustry associations from across the Rocky Mountain and Southwest Region are presenting an opportunity for angel investors, venture capitalists and strategic investors to connect with biotech and healthcare investment opportunities.

At the conference, Fluonic will discuss its technology and flagship product, the SURE+ fully disposable infusion system. The system, which measures the actual flow rate to the patient in real time, allows remote monitoring of the infusion procedure, and provides auto adjustments and alarms.

Creating a new standard of care
“The White Hat Conference will give Fluonic the opportunity to present a cost-effective, scalable solution for a problem that has afflicted the health care industry for more than 30 years,” says Jim Kasic, CEO of Fluonic. While more than 90 percent of hospitalized patients receive some type of intravenous drug therapy, and hundreds of thousands more receive intravenous drug therapy at home or on an out-patient basis, the pumps that deliver the medication operate blindfolded, unable to verify what they actually deliver to the patient, he explains. The industry is plagued with recalls of hundreds of thousands of faulty pumps. “The situation is an unacceptable one for a life-dependent medical system,” says Kasic.

Fluonic’s sensor, Kasic states, is accurate over the entire flow range, delivers information on the medication flow to designated recipients, wirelessly, and senses very low flows very precisely. As a result, health care providers can better control infusion drug delivery, and patients can receive more types of drugs at home, effectively reducing hospital stays and visits, and outpatient clinic visits. “Fluonic is creating the opportunity for a new standard of care, taking the questions and guesswork out of infusion drug therapy.”

Fluonic, Inc. (http://www.fluonic.com)
Based in Boulder, Colo., Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s products, including the flagship VariFlow sensor, solve the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows. Initial applications include elastomeric infusion pumps and critical care equipment.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aimee Bennett

Jim Kasic
Visit website